Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avapritinib (BLU-285) 是选择性的、高效的、具有口服活性的 KIT 和 PDGFRA 激活环突变激酶抑制剂,能够作用于 KIT D816V (IC50:0.27 nM) 和 PDGFRA D842V (IC50:0.24 nM)。它减弱 ABCB1 和 ABCG2 的传输功能。它与激酶的活性构象结合,并显示抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 596 | 现货 | ||
5 mg | ¥ 1,390 | 现货 | ||
10 mg | ¥ 2,130 | 现货 | ||
25 mg | ¥ 3,920 | 现货 | ||
50 mg | ¥ 5,680 | 现货 | ||
100 mg | ¥ 7,930 | 现货 | ||
500 mg | ¥ 15,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,550 | 现货 |
产品描述 | Avapritinib (BLU-285) is a dual inhibitor of the mutant KIT receptor (KIT D816V, IC50: 0.27 nM) and PDGFRα (PDGFRα D842V, IC50: 0.24 nM). |
靶点活性 | c-Kit (D816V):0.27 nM, PDGFRα (D842V):0.24 nM |
体外活性 | Cellular activity of Avapritinib on KIT D816 mutants is measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50=4 and 22 nM, respectively. In Kasumi-1 cells, at positive AML cell line with a KIT exon 17 N822K mutation, Avapritinib potently inhibits KIT N822K mutant autophosphorylation (IC50: 40 nM), downstream signaling, as well as cellular proliferation (IC50: 75 nM)[1]. |
体内活性 | BLU-285 (0.3-30 mg/kg) reduces tumor volume in a P815 KITD814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner. Formulations containing BLU-285 have been used to treat KIT- and PDGFRα-driven malignancies. |
动物实验 | A Kasumi-1 luc+ AML NOG SCID mouse femoral injection model is used to assess the efficacy of Avapritinib (BLU-285) in KIT exon 17-mutated CBF-AML. Following a 21 day post-injection latency period, mice are dosed with Avapritinib orally, once daily at 10 mg/kg or 30 mg/kg through day 45. Control groups are treated with vehicle or Cytarabine administered 100 mg/kg i.p once weekly. |
别名 | BLU-285 |
分子量 | 498.56 |
分子式 | C26H27FN10 |
CAS No. | 1703793-34-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
Ethanol: 3 mg/mL
DMSO: 50 mg/mL (100.29 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0058 mL | 10.0289 mL | 20.0578 mL | 50.1444 mL |
5 mM | 0.4012 mL | 2.0058 mL | 4.0116 mL | 10.0289 mL | |
10 mM | 0.2006 mL | 1.0029 mL | 2.0058 mL | 5.0144 mL | |
20 mM | 0.1003 mL | 0.5014 mL | 1.0029 mL | 2.5072 mL | |
50 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 1.0029 mL | |
100 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5014 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Avapritinib 1703793-34-3 Angiogenesis Tyrosine Kinase/Adaptors PDGFR c-Kit CD117 Platelet-derived growth factor receptor BLU-285 BLU285 SCFR Inhibitor BLU 285 inhibit inhibitor